LOGIN
No effect of GLP-1 receptor agonists on fracture incidence in type 2 diabetes treatment
December 2016
No effect of GLP-1 receptor agonists on fracture incidence in type 2 diabetes treatment
Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A
Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials
J Diabetes. 2014 May;6(3):260-6. doi: 10.1111/1753-0407.12102. Epub 2013 Nov 22Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Seven randomized controlled trials were included in this meta-analysis investigating the effect of glucagon-like peptide (GLP)-1 receptor agonists on bone fracture incidence in patients with type 2 diabetes mellitus. The purpose was to determine if treatment with GLP-1 receptor agonists led to a significantly lower rate of bone fracture when compared to either placebo or other antidiabetic drugs. ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Join the Conversation
Please Login or Join to leave comments.